Sunshine Biopharma ( (SBFM) ) has released a notification of late filing.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Sunshine Biopharma has filed a Form 12b-25, indicating a delay in submitting its Form 10-K (Yearly Report) and Form 10-Q (Quarter Report) for the financial period ending December 31, 2024. The delay is primarily due to the need for additional time to complete its financial statements. The company anticipates filing the delayed reports within the regulatory grace period, which is the fifteenth calendar day for the yearly report and the fifth calendar day for the quarterly report following the due date. Sunshine Biopharma does not expect any significant changes in its financial results compared to the previous year. The notification was signed by Dr. Steve N. Slilaty, the CEO, indicating the company’s commitment to resolving the delay promptly.
More about Sunshine Biopharma
YTD Price Performance: -36.10%
Average Trading Volume: 66,942
Technical Sentiment Signal: Strong Buy
Current Market Cap: $5.42M
For a thorough assessment of SBFM stock, go to TipRanks’ Stock Analysis page.